Bremelanotide
PT-141, Vyleesi
The only approved drug that works on desire in the brain rather than blood flow in the tissue. Different mechanism from Viagra, and a different problem.
FDA-approved
FDA-approved in June 2019 as Vyleesi, for acquired generalised hypoactive sexual desire disorder in premenopausal women. Every other use, including all use by men, is off-label.
What it is
Bremelanotide activates melanocortin receptors, mainly MC4R, in the central nervous system. It does not touch blood flow. It acts on the neural circuits that generate desire in the first place.
That distinction is the whole point of the drug. PDE5 inhibitors like tadalafil solve a plumbing problem: the desire is there, the vascular response is not. Bremelanotide addresses the opposite case. If wanting is the thing that has gone missing, no amount of improved blood flow fixes it, and people spend years on the wrong drug for exactly this reason.
What the evidence shows
Approval rests on two identical 24-week randomised placebo-controlled trials in 1,247 premenopausal women with acquired generalised HSDD. Both hit their co-primary endpoints on desire and on distress related to low desire.
Worth being straight about the size of the effect. It is statistically solid and clinically modest. This is not a switch that flips libido back on; it is a measurable shift in a difficult condition that previously had almost nothing. Roughly 40% of participants reported nausea, and that number explains most of the discontinuations.
In men, there is no approval and no equivalent evidence base. Bremelanotide was studied in male erectile dysfunction years ago, including an intranasal formulation that was dropped over blood pressure signals. Most male use today rests on self-report.
Practical notes
- Nausea is the defining side effect, which is why community doses often land well below the approved 1.75 mg. Lower doses trade effect for tolerability, and nobody has formally studied where that curve sits.
- Timing is roughly 45 minutes ahead, and the effect window is a few hours rather than tadalafil's day and a half.
- The monthly cap exists for a reason. Repeated dosing drives pigmentation changes, and the blood pressure effect is real if modest.
- Do not combine it with melanotan II. They are close relatives at the same receptor family, and stacking them compounds both the pigmentation and the cardiovascular effects.
Side effects and warning signs
Commonly reported
- Nausea, reported by about 40% of trial participants and the main reason people stop
- Flushing and headache
- Injection-site reactions
- Transient blood pressure rise with a small drop in heart rate, peaking within an hour
- Darkening of skin, gums or face with repeated use, more likely in people with darker skin
Stop and get medical help
- Uncontrolled hypertension or known cardiovascular disease, which the label lists as a contraindication
- Any new or changing pigmented lesion, since this is a melanocortin agonist
- Nausea severe enough to cause vomiting and dehydration
Sources
From the community
Discussion for this compound concentrates in r/Peptidesource and r/PeptideForum.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.